替米沙坦对肝纤维化大鼠肝组织病理学变化的影响

目的观察替米沙坦对四氯化碳（CCl4）诱导的大鼠实验性肝纤维化模型肝组织病理学变化的影响。方法 SD大鼠40只被随机分成正常对照组（12只）、模型组（12只）和替米沙坦防治组（16只）。在制备大鼠肝纤维化动物模型成功后,取肝、脾,常规进行组织病理学检查。结果模型组大鼠平均肝指数为4.85±0.42（P〈0.05）,正常对照组为2.92±0.41,而药物干预组为3.09±0.36;模型组大鼠肝炎症活动度平均计分为18.6±2.1（P〈0.05）,正常对照组为0.0±0.0,替米沙坦干预组为8.6±1.9;模型组大鼠肝纤维化计分平均为14.5±1.6,正常对照组为0.33±0.49,替米沙坦干预组为7.7±1.7（P〈0.01）。结论替米沙坦可改善实验性纤维化大鼠肝组织病理学损伤。

Study on pathologic changes of hepatic fibrosis by telmisartan in experimental rats

Objective To investigate the effect of telmisartan on hepatic fibrosis induced by CCl4 in experimental rats.Methods Total 40 male SD rats were randomly divided into 3 groups,i.e,control(n=12),model(n=12)and telmisartan groups(n=16).The liver fibrotic model was induced by CCl4 and the liver pathological changes were observed.Results The liver index in model was 4.85±0.42,in control was 2.92±0.41 and in interventional group was 3.09±0.36(P<0.05);The HAI in model was 18.6±2.1,in normal was 0.0±0.0 and in telmisartan group was 8.6±1.9(P<0.01);the hepatic fibrosis scores in model was 14.5±1.6,in control was 0.33±0.49 and in telmisartan group was 7.7±1.7(P<0.01).Conclusions Telmisartan can improve the hepatic fibrosis in rats.